Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
Johnson and Johnson
US Department of Justice
Colorcon
Argus Health
Medtronic
Merck
Julphar
Farmers Insurance

Generated: April 21, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 050790

« Back to Dashboard

NDA 050790 describes RESTASIS MULTIDOSE, which is a drug marketed by Allergan and is included in one NDA. It is available from two suppliers. There are ten patents protecting this drug. Additional details are available on the RESTASIS MULTIDOSE profile page.

The generic ingredient in RESTASIS MULTIDOSE is cyclosporine. There are eighteen drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the cyclosporine profile page.
Summary for 050790
Tradename:RESTASIS MULTIDOSE
Applicant:Allergan
Ingredient:cyclosporine
Patents:10
Therapeutic Class:Immunological Agents
Ophthalmic Agents
Formulation / Manufacturing:see details
Suppliers and Packaging for NDA: 050790
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
RESTASIS cyclosporine EMULSION;OPHTHALMIC 050790 NDA Allergan, Inc. 0023-5301 N 0023-5301-05
RESTASIS MULTIDOSE cyclosporine EMULSION;OPHTHALMIC 050790 NDA Allergan, Inc. 0023-5301 N 0023-5301-05

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:EMULSION;OPHTHALMICStrength0.05%
Approval Date:Dec 23, 2002TE:RLD:Yes
Patent:➤ Try a Free TrialPatent Expiration:Aug 27, 2024Product Flag?YSubstance Flag?Delist Request?
Patent:➤ Try a Free TrialPatent Expiration:Aug 27, 2024Product Flag?Substance Flag?Delist Request?
Patented Use:INCREASE TEAR PRODUCTION TO TREAT PATIENTS WITH KERATOCONJUNCTIVITIS SICCA (DRY EYE).
Patent:➤ Try a Free TrialPatent Expiration:Aug 27, 2024Product Flag?YSubstance Flag?Delist Request?

Expired US Patents for NDA 050790

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Allergan RESTASIS cyclosporine EMULSION;OPHTHALMIC 050790-001 Dec 23, 2002 ➤ Try a Free Trial ➤ Try a Free Trial
Allergan RESTASIS cyclosporine EMULSION;OPHTHALMIC 050790-001 Dec 23, 2002 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
Chinese Patent Office
Cipla
Merck
McKinsey
AstraZeneca
Fish and Richardson
Baxter
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.